Valuation: Mylan Inc

Market Cap 1.89TCr 1.66TCr 1.53TCr 1.41TCr 2.68TCr 1,80700Cr 2.72TCr 18TCr 7.17TCr 89TCr 7.11TCr 6.96TCr 3,06000Cr P/E 2026 *
69.8x
P/E 2027 * 25.8x
Enterprise Value 3.11TCr 2.72TCr 2.51TCr 2.32TCr 4.4TCr 2,96900Cr 4.48TCr 30TCr 12TCr 1,46300Cr 12TCr 11TCr 5,02900Cr EV / Sales 2026 *
2.11x
EV / Sales 2027 * 1.99x
Free-Float
92.23%
Yield 2026 *
3.13%
Yield 2027 * 3.21%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-2.09%+49.88%+170.51% 1,06000Cr
-0.82%-2.30%+63.79%+62.00% 62TCr
-0.73%-4.98%+28.91%+82.99% 44TCr
+0.33%-1.17%+31.07%+27.09% 33TCr
-0.02%-2.85%+29.15%+45.24% 28TCr
-3.89%-11.22%+22.81%+27.30% 27TCr
+0.66%-1.42%-26.59%-37.71% 22TCr
-0.06%-2.88%+23.07%+62.33% 20TCr
-3.72%-1.10%+18.41%+70.56% 16TCr
Average -1.18%-3.25%+26.72%+56.70% 39.71TCr
Weighted average by Cap. -1.31%-2.96%+36.75%+83.91%

Financials

2026 *2027 *
Net sales 1.48TCr 1.29TCr 1.19TCr 1.1TCr 2.09TCr 1,40900Cr 2.12TCr 14TCr 5.59TCr 69TCr 5.55TCr 5.43TCr 2,38600Cr 1.5TCr 1.32TCr 1.21TCr 1.12TCr 2.13TCr 1,43400Cr 2.16TCr 14TCr 5.69TCr 71TCr 5.65TCr 5.52TCr 2,42900Cr
Net income 1.3Cr 1.14Cr 1.05Cr 96.85L 1.84Cr 123.96Cr 1.87Cr 13Cr 4.92Cr 61Cr 4.88Cr 4.77Cr 209.94Cr 50Cr 44Cr 40Cr 37Cr 70Cr 4.75TCr 72Cr 479.62Cr 188.35Cr 2.34TCr 186.81Cr 182.74Cr 8.04TCr
Net Debt 1.22TCr 1.07TCr 983.23Cr 908.11Cr 1.72TCr 1,16200Cr 1.75TCr 12TCr 4.61TCr 57TCr 4.58TCr 4.48TCr 1,96800Cr 1.1TCr 964.84Cr 889.94Cr 821.95Cr 1.56TCr 1,05200Cr 1.59TCr 11TCr 4.18TCr 52TCr 4.14TCr 4.05TCr 1,78200Cr
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-